The economic impact of the opioid epidemic Julia Paris, Caitlin Rowley, and Richard G. Frank Monday, April 17, 2023
Medicare Advantage spending, medical loss ratios, and related businesses: An initial investigation Richard G. Frank and Conrad Milhaupt Friday, March 24, 2023
Threats to Medicare’s new drug negotiation power Richard G. Frank and Len M. Nichols Wednesday, March 15, 2023
Play Video Key economic policy developments in 2022 and what to expect in 2023 Wendy Edelberg, Richard G. Frank, Aaron Klein, Sanjay Patnaik, and David Wessel Wednesday, December 21, 2022
Some drugs that improve price competition fall through the cracks of FDA user fees Marta E. Wosińska and Richard G. Frank Monday, December 12, 2022
Profits, medical loss ratios, and the ownership structure of Medicare Advantage plans Richard G. Frank and Conrad Milhaupt Wednesday, July 13, 2022
To prevent public health crises, we need to update the essential medical product list Marta E. Wosińska and Richard G. Frank Friday, June 24, 2022
5 things to understand about pharmaceutical R&D Richard G. Frank and Kathleen Hannick Thursday, June 2, 2022
Tackling unfinished business and taking on current challenges: Putting Biden’s mental health proposals in context Richard G. Frank, Vikki Wachino, and Karina Aguilar Monday, April 4, 2022
